Opinion

Video

Personalizing ADC Therapy in mBC Based on Patient Characteristics and Prior Therapies

Panelists discuss how patient characteristics significantly impact antibody-drug conjugate (ADC) therapy selection, with key factors including the presence and location of brain metastases (due to blood-brain barrier penetration), organ function and comorbidities affecting toxicity risks, and prior treatment history that may influence both efficacy and safety. Treatment decisions require careful individualization.

Video content above has been prompted by the following:

  • How do patient characteristics (eg, brain metastases, other comorbidities, prior therapies) influence ADC therapy selection?
Related Videos
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video